Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 2,554,764 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,311,837 | 3,145,402 |
| Accumulated other comprehensive loss | (33,897) | (25,281) |
| Accumulated deficit | (2,838,369) | (2,631,195) |
| Total stockholders' equity | 439,737 | 489,089 |
| Total liabilities and stockholders’ equity | $$2,994,501 | 3,523,836 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's AOCI?
- Ionis Pharmaceuticals (IONS) reported AOCI of -$33.9M in Q2 2026.
- How has Ionis Pharmaceuticals's AOCI changed year-over-year?
- Ionis Pharmaceuticals's AOCI decreased by 21.1% year-over-year, from -$27.99M to -$33.9M.
- What is the long-term trend for Ionis Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's AOCI has grown at a 3.7% compound annual growth rate (CAGR), from -$21.07M to -$25.28M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Ionis Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude